Side-by-side comparison of AI visibility scores, market position, and capabilities
Bengaluru/Boston robotic digital pathology with RoboTome (2x sectioning speed) and MorphoLens (100+ slides/hour); $5M Series A Nov 2025 Inflexor Ventures with 80+ patents and US/European lab deployments competing with Leica for histopathology automation.
Morphle Labs is a Bengaluru, India and Boston, Massachusetts-based robotic microscopy and digital pathology company — raising $5 million in Series A funding in November 2025 led by Inflexor Ventures — providing histopathology laboratories with AI-powered physical automation platforms that address the speed and throughput bottlenecks in cancer diagnostics workflows. With 80+ patents filed and products deployed in leading US and European laboratories, Morphle's 100-member team has developed two flagship platforms: RoboTome (a robotic microtome system that slices biopsy tissue blocks at 2x the speed of experienced histotechnologists) and MorphoLens (a high-throughput slide scanner that digitizes 100+ histology slides per hour for digital pathology review). Founded to "revolutionize cancer diagnostics with physical AI," Morphle expands manufacturing, regulatory clearances, and global presence with the Series A.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.